DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Norovirus" report has been added to ResearchAndMarkets.com's offering.
This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, key upcoming events, and an epidemiological overview.
- Worldwide, about one out of every five cases of acute gastroenteritis is associated with norovirus. Norovirus is responsible for approximately 685 million cases of gastroenteritis every year.
- Globally, norovirus is estimated to cause approximately 200,000 deaths annually, with at least 50,000 being children, mainly in developing countries.
- There are four clinical candidates in development for norovirus; two in Phase I and two in Phase II. The majority of clinical candidates currently in the pipeline for norovirus are vaccines. These are administered via the oral, intranasal, and intramuscular routes.
- Topline Phase IIb trial results for Monovalent Norovirus VLP Vaccine is the only high-impact upcoming event for drugs in the norovirus space.
- The overall likelihood of approval of a Phase I antiviral asset is 16.2%, and the average probability a drug advances from Phase III is 75.9%. Drugs, on average, take 8.6 years from Phase I to approval, compared to 9 years in the overall infectious disease space.
- The clinical trials distribution across Phase I-III indicates that the vast majority of trials for norovirus have been in the early and mid-phases of development, with 91% of trials in Phase I-II, and only 9% in Phase III.
- Takeda has the highest number of completed and planned clinical trials for norovirus, with eight trials in each category. Takeda also leads industry sponsors with by far the highest overall number of clinical trials for norovirus, followed by Vaxart.
Key Topics Covered
Challenges for vaccine development
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
LIST OF FIGURES
Figure 1: Overview of pipeline drugs for norovirus in the US
Figure 2: Pipeline drugs for norovirus, by company
Figure 3: Pipeline drugs for norovirus, by drug type
Figure 4: Pipeline drugs for norovirus, by classification
Figure 5: Key upcoming events in norovirus
Figure 6: Probability of success in the norovirus pipeline
Figure 7: Clinical trials in norovirus
Figure 8: Top 10 drugs for clinical trials in norovirus
Figure 9: Top 10 companies for clinical trials in norovirus
Figure 10: Norovirus trials status
Figure 11: Norovirus trials sponsors, by phase
LIST OF TABLES
Table 1: Pipeline drugs for norovirus in the US
For more information about this report visit https://www.researchandmarkets.com/r/hw3ls
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets